We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Familial Hypercholesterolemia Patients With ACD Have Elevated Lipoprotein(a)

By LabMedica International staff writers
Posted on 22 Nov 2022
Print article
Image: Equivalence of Genetically Elevated LDL and Lipoprotein(a) on Myocardial Infarction (Photo courtesy of Viborg Regional Hospital)
Image: Equivalence of Genetically Elevated LDL and Lipoprotein(a) on Myocardial Infarction (Photo courtesy of Viborg Regional Hospital)

Familial hypercholesterolemia (FH) is a genetic disorder characterized by high cholesterol levels, specifically very high levels of low-density lipoprotein (LDL cholesterol), in the blood and early cardiovascular disease.

Genetically elevated plasma lipoprotein(a) and familial hypercholesterolemia each result in premature atherosclerotic cardiovascular disease (ASCVD); however, a direct comparison in the same population is needed of these two genetic traits on the risk of ASCVD.

Clinical Biochemists at the Viborg Regional Hospital (Viborg, Denmark) and their colleagues determined the level of plasma lipoprotein(a) that is equivalent to low-density lipoprotein (LDL) cholesterol in clinically and genetically diagnosed familial hypercholesterolemia on risk of myocardial infarction and ASCVD. They examined the CGPS (Copenhagen General Population Study) with determination of lipoprotein(a) and familial hypercholesterolemia in 69,644 individuals followed for 42 years, during which time, 4,166 developed myocardial infarction and 11,464, ASCVD. Lipid levels were measured using blood samples drawn in the non-fasting state.

The investigators reported that in patients with FH, a plasma Lp(a) level of 67 mg/dL to 402 mg/dL was equivalent to an LDL of 180 mg/dL in risk for myocardial infarction (MI), whereas a Lp(a) level of 130 mg/dL to 391 mg/dL was equivalent to an LDL of 175 mg/dL in risk for ASCVD.

Moreover, people with both elevated Lp(a) and either FH or a family history of premature MI had greater risk for MI and ASCVD compared with those with either genetic risk factor alone, according to the study. In people with either FH or a family history of premature MI, those with Lp(a) in the upper 20% had the highest risk for MI (HR = 14) and ASCVD (HR = 5.05) compared with those with Lp(a) in the lower 50% ( 10 mg/dL).

Berit Storgaard Hedegaard, RN, the lead author of the study, said, “The present direct comparison of conventionally diagnosed elevated plasma lipoprotein(a) with clinical and genetic FH in the same population provides for the first time the levels of plasma lipoprotein(a) that are equivalent to LDL cholesterol in FH on risk of MI and ASCVD.”

The authors concluded that lipoprotein(a) levels equivalent to LDL cholesterol in clinical and genetic familial hypercholesterolemia were 67 to 402 mg/dL and 180 mg/dL, respectively, for myocardial infarction and 130 to 391 mg/dL and 175 mg/dL, respectively, for ASCVD. They emphasized the importance of measuring lipoprotein(a) in patients with FH as well as the importance of evaluating patients with elevated lipoprotein(a) for FH. The study was published in the November 2022 issue of the Journal of the American College of Cardiology.

Related Links:
Viborg Regional Hospital

Gold Supplier
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Sepsis Test
C-Reactive Protein Test
PLUS CRP Turbilatex
POC Quantitative Immunoassay Platform
ProciseDx Instrument

Print article


Molecular Diagnostics

view channel
Image: A cheap blood test could improve diagnosis of myocarditis (Photo courtesy of Queen Mary University of London)

First-Ever Blood Test Could Detect Deadly Heart Inflammation Within Hours

Myocarditis, or inflammation of the heart muscle, is a difficult condition to diagnose. Symptoms include a temperature, fatigue, chest pain and shortness of breath, which can all be easily mistaken for... Read more


view channel
Image: Ring-form trophozoites of Plasmodium vivax in a thin blood smear (Photo courtesy of Centers for Disease Control and Prevention)

Immune Regulators Predict Severity of Plasmodium vivax Malaria

Cytokines and chemokines are immune response molecules that display diverse functions, such as inflammation and immune regulation. In Plasmodium vivax infections, the uncontrolled production of these molecules... Read more


view channel
Image: Breast cancer spread uncovered by new molecular microscopy (Photo courtesy of Wellcome Sanger Institute)

New Molecular Microscopy Tool Uncovers Breast Cancer Spread

Breast cancer commonly starts when cells start to grow uncontrollably, often due to mutations in the cells. Overtime the tumor becomes a patchwork of cells, called cancer clones, each with different mutations.... Read more


view channel
Image: With Cell IDx’s acquisition, Leica Biosystems will be moving its multiplexing menu forward (Photo courtesy of Leica Biosystems)

Leica Biosystems Acquires Cell IDx, Expanding Offerings in Multiplexed Tissue Profiling

Leica Biosystems, a technology leader in automated staining and brightfield and fluorescent imaging (Nussloch, Germany), has acquired Cell IDx, Inc. (San Diego, CA, USA), which provides multiplex staining... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.